CandlesenseCandlesense
KALV•benzinga•

KalVista Pharma Q3 2025 GAAP EPS $(0.92) Misses $(0.87) Estimate, The Company Had Cash, Cash Equivalents And Marketable Securities Of Approximately $253.2M

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 12, 2025 by benzinga

← Back to KALV News
    KalVista Pharma Q3 2025 GAAP EPS $(0.92) Misses $(0.87) Estimate, The Company Had Cash, Cash Equivalents And Marketable Securities Of Approximately $253.2M | KALV Stock News | Candlesense